Advocacy Actions
Submitted comments to the NPC on the Biosecurity Law
The National People’s Congress (NPC) issued a call for comments on the Biosecurity Law (the second draft for review) with an official deadline on 13th June.
Read moreComments to SAMR on Draft Revisions to the Anti-monopoly Law of the People's Republic of China (Draft for Comment)
The European Chamber very much welcomes the SAMR's decision to collect opinions on the "Draft Revisions to the Anti-monopoly Law of the People's Republic of China (Draft for Comment)". Upon careful study of the draft and consultation with its members, the European Union Chamber of Commerce in China, led by its Legal and Compliance Working Group, has collated all member inputs and submitted suggestions to the SAMR Anti-monopoly Bureau for their consideration.
Read moreLetter to Medical Insurance Department of MOHRSS on Drug Renaming in NRDL
Letter to Medical Insurance Department of MOHRSS on Drug Renaming in NRDL
Read moreComments on CFDA's Announcement 52, 53, 54, 55 on Encouraging Innovation in Pharmaceutical and Medical Devices
European Chamber Pharmaceutical Working Group submitted comments on CFDA's Announcement No. 52, 53, 54, 55 on encouraging innovation in pharmaceutical and medical device.
Read moreComments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
European Chamber Comments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
Read moreComments on Anti-unfair Competition Law (Draft Revision)
The European Chamber submitted consolidated comments from member companies to the National People's Congress on Anti-unfair Competition Law (Draft Revision).
Read moreSpeech at the 2017 International Pharmaceutical Innovation Forum in Nanjing
European Chamber Secretary General Mr. Adam Dunnett gave a keynote speech at 2017 International Pharmaceutical Innovation Forum in Nanjing, raising European businesses' recommendations on promoting innovation in China
Read moreLobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Lobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Read more